University Multiprofile Hospital For Active Treatment Sofiamed OOD
- Address
- lock Available on a paid plan
UMHAT Sofiamed OOD - Advanced Oncology and Complex Disease Research
UMHAT Sofiamed OOD is a comprehensive clinical research facility specializing in cutting-edge therapeutic trials across multiple complex disease areas. The center demonstrates particular expertise in precision oncology, with extensive experience in targeted therapies for lung, prostate, breast, and gastrointestinal cancers. Their research portfolio encompasses novel immunotherapy combinations, targeted molecular therapies, and biosimilar development, positioning them at the forefront of personalized cancer treatment.
- Advanced lung cancer therapeutics, including EGFR-mutated and HER2-mutated NSCLC, with expertise in immunotherapy combinations and antibody-drug conjugates
- Prostate cancer precision medicine, focusing on PTEN-deficient and castration-resistant disease with novel hormonal and targeted therapies
- Complex metabolic and hepatic conditions, including chronic hepatitis B functional cure strategies, NASH, severe hypertriglyceridemia, and type 2 diabetes management
- Immunological and hematological disorders, encompassing systemic lupus erythematosus, immune thrombocytopenia, and hypogammaglobulinemia associated with hematologic malignancies
The center's research extends to gastrointestinal malignancies including BRAF-mutated colorectal cancer and urothelial carcinomas, as well as autoimmune conditions such as ulcerative colitis and Graves' disease. UMHAT Sofiamed also participates in cardiovascular outcome studies for acute myocardial infarction and infectious disease trials including respiratory syncytial virus. Their capability to manage complex Phase 2 and Phase 3 multinational trials, combined with expertise in specialized endpoints such as radiographic progression-free survival and functional cure assessments, makes them a valuable partner for pharmaceutical innovation across diverse therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 23 therapeutic areas and 15 of 94 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 94 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Pfizer Inc.2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Multiprofile Hospital For Active Treatment Sofiamed OOD
lock Showing 1 of 47 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 94 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 7 | Unknown | 2018-11-30 | 2024-10-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.